X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AU-007 is a human IgG1 monoclonal antibody designed to harness the power of interleukin-2 (IL-2) to eradicate solid tumors. It is being evaluated in phase 1/2 clinical trials for the treatment of advanced melanoma, advanced renal cell carcinoma.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. It is under phase 1/2 clinical development for the treatment of solid tumors.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The funds will be used to advance Aulos’ lead human monoclonal antibody candidate, AU-007 that is highly selective to the CD25-binding portion of IL-2, through its initial Phase 2 clinical study in solid tumor cancers.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Apple Tree Partners
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 01, 2023
Details:
AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages IL-2 to reinforce anti-tumor immune effects.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2.AU-007 leverages IL-2 to reinforce anti-tumor immune effects.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages IL-2 to reinforce anti-tumor immune effects.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
AU-007 is a human monoclonal antibody computationally designed by Biolojic Design, with a highly differentiated approach to harnessing the power of interleukin-2 (IL-2) to eradicate solid tumors.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biolojic Design
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages IL-2 to reinforce anti-tumor immune effects.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
The trial will evaluate AU-007, a highly differentiated monoclonal antibody that was computationally designed by Biolojic and harnesses the power of the body's own interleukin-2 (IL-2) to eradicate solid cancer tumors.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biolojic Design
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
Data show significant tumor growth inhibition with AU-007, a computationally designed, human IgG1 monoclonal antibody, and complete tumor eradication when dosed in combination with checkpoint inhibitors.
Lead Product(s): AU-007,Undisclosed
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
